A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Trial Profile

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs CPI 444 (Primary) ; CPI-006 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Corvus Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Mar 2018 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT03454451).
    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top